Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01874080 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01874080 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 56 participants.
The verdict
NCT01874080, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if tablets manufactured at different sites have the same bioavailability, that is yield similar blood levels/concentrations of the drugs and are handled by the body similarly
Interventions
- DRUG Saxagliptin/Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01874080
The ClinicalTrials.gov registry entry for NCT01874080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saxagliptin/Metformin is the first listed.
NCT01874080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01874080 about?
NCT01874080 is a clinical study titled "Bioequivalence Study". The purpose of this study is to determine if tablets manufactured at different sites have the same bioavailability, that is yield similar blood levels/concentrations of the drugs and are handled by the body similarly
What is the current status of trial NCT01874080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2013-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01874080?
The interventions under investigation include: Saxagliptin/Metformin (DRUG).
Who is sponsoring clinical trial NCT01874080?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.